ESR1 and prostate carcinoma: One of the PROTAC, ARV-110, which targets androgen receptors in prostate cancer, completed phase 2 clinical trials, and ARV-471, which targets estrogen receptor in breast cancer, also completed phase 2 clinical trials [172].